Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

  title={Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring},
  author={Ludwig Kappos and David W. Bates and H. P. Hartung and Eva Kubala Havrdov{\'a} and David Miller and Chris H. Polman and Mads Henrik Ravnborg and Stephen L. Hauser and Richard A. Rudick and Howard L. Weiner and P. W. O'Connor and John O King and Ernst-Wilhelm Radue and Tarek A. Yousry and Eugene O. Major and David B. Clifford},
  journal={The Lancet Neurology},

Figures and Tables from this paper

Natalizumab for multiple sclerosis: a complicated treatment

Best practice in the use of natalizumab in multiple sclerosis

  • Ó. Fernández
  • Medicine, Psychology
    Therapeutic advances in neurological disorders
  • 2013
The recent availability of a two-step enzyme-linked immunosorbent assay (ELISA) test for the presence of anti-JCV antibodies, along with an ever-improving understanding of other risk factors, allow an increasingly refined stratification of the risk of PML.

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.

In the setting of early diagnosis and consequent treatment, natalizumab-associated PML can be well managed in some cases, which differs from the course of PML in other conditions, eg, after the application of depleting monoclonal antibodies.

Review: Natalizumab in the treatment of multiple sclerosis

Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42—54% over 2 years in its pivotal phase III trial (AFFIRM) in

Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update

The purpose of this article is to revise and add to the previous publications to reflect the latest available knowledge on the use of natalizumab, including long-term efficacy and real-world safety data with natalIZumab in MS, appropriate monitoring strategies for treated patients, and use of the anti-JCV antibody index in risk stratification for natalizzumabassociated PML.

Natalizumab treatment in pediatric multiple sclerosis: a case report.




Natalizumab: Immune effects and implications for therapy

Two articles in this issue of Annals provide the first detailed look at immunological effects of natalizumab treatment in patients with MS, and demonstrate that treatment dramatically reduces the number of cerebrospinal fluid mononuclear cells.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.

Progressive multifocal leucoencephalopathy and immunosuppression.

We report an immunocompromised patient with progressive multifocal leucoencephalopathy (PML), who demonstrates the usefulness and limitation of the algorithm of Warnatz et al 1 for investigation of

Progressive multifocal leukoencephalopathy in patients with HIV infection.

Progressive multifocal leukoencephalopathy often heralds AIDS and may occur in the absence of significant decline in CD4 lymphocytes, and survival is generally poor, although prolonged survival beyond 1 year is not unusual.

Progressive multifocal leukoencephalopathy in transplant recipients

Progressive multifocal leukoencephalopathy is a unique entity that should be considered in any transplant recipient with neurological symptoms and is usually fatal, although regression has been reported.

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.

Opportunistic Infections of the CNS in Patients with AIDS

Effective treatments are available for toxoplasmosis and cryptococcosis, although adverse effects are common and some patients may not respond to therapy, and the efficacy of anticytomegalovirus therapy is poor and the toxicity significant.

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.

Virologic and serologic studies of progressive multifocal leukoencephalopathy.

The human polyomavirus JCV has been associated with diseased brain tissue from 54 cases of PML, and preliminary studies indicate that one isolate, while clearly of JCV type, is serologically distinguishable from prototype Mad 1 JCV.